From a clinical perspective, the work by Bröker-Lai et al, has the great merit of uncovering a new role for TRPC5 in the control of the adrenergic counter-response to hypoglycemia and suggests TRPC5 as a likely potential target for diagnostic and pharmacological intervention in patients with diabetes and HAAF complications. This evidence concerns the gene TRPC5 and diabetes mellitus.